Spotlight On... Pfizer joins Human Vaccines Project; PATH to open 'Center for Vaccine Innovation and Access' with $11M Gates Foundation grant; Cadila shares suffer on WHO plant inspection report; and more…

FDA

Pfizer ($PFE) enlisted in the Human Vaccines Project, joining an influential group of peers and research institutions setting out to "decode the human immune system." Founded at the International AIDS Vaccine Institute, the Human Vaccines Project so far has participation from a broad range of pharma partners and academic institutions, hoping that knowledge gained through the partnership will help in the development of vaccines against infectious diseases, cancer, flu, dengue and other targets. In addition to Pfizer, participants so far are Regeneron ($REGN), GlaxoSmithKline ($GSK), AstraZeneca's ($AZN) MedImmune, Sanofi Pasteur, Janssen, among others. Release

> Seattle-based nonprofit PATH plans to open a "Center for Vaccine Innovation and Access," with initial funding in the amount of $11 million coming from the Bill & Melinda Gates Foundation, according to reports. Release | More

> WHO regulators noted "several major deviations" at a Cadila Healthcare vaccine plant in India following a recent inspection, sending the company's shares downward. Report

Whitepaper

Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

> Soligenix netted $660,000 in NIAID funding to advance regulatory interactions on its heat stable ricin vaccine. Release

> Hyderabad-based Biological E received a Rs895 crore ($134 million) order from the country's health ministry to provide its 5-in-1 liquid pentavalent vaccine for the universal vaccination program. Report

Read more on

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.